Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing, and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centers in Denmark and China.

Research Grants 51 show all


$37M
2015

$37.7M
2016

$14.5M
2017

$5.4M
2018

$25.1M
2019

Publications 1 show all

  • 1
    Bipolar Disorder/genetics
  • 1
    Immunity, Innate/genetics
  • 1
    Mannose-Binding Lectin/genetics
  • 1
    Mannose-Binding Protein-Associated Serine Proteases/genetics
  • 1
    Panic Disorder/genetics

Patents 7,541show all

  • 1,928
    C07D - Heterocyclic compounds
  • 1,064
    A61K - Preparations for medical, dental, or toilet purposes
  • 223
    C07C - Acyclic or carbocyclic compounds
  • 144
    C07K - Peptides
  • 112
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 54
    C07B - General methods of organic chemistry
  • 52
    A01K - Animal husbandry
  • 33
    C12N - Microorganisms or enzymes
  • 24
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 24
    Y02A - Technologies for adaptation to climate change

Clinical Trials 767show all

281N/A242Phase 371Phase 169Phase 261Phase 48Other

Contact Information

Overview

Total FundingEmployeesLast Funding DateStatus
5001-10000Ipo